AAAAAA

   
Results: 1-19 |
Results: 19
Resistance to antiretroviral therapy among patients in Uganda
Authors: Weidle, PJ Kityo, CM Mugyenyi, P Downing, R Kebba, A Pieniazek, D Respess, R Hertogs, K De Vroey, V Dehertogh, P Bloor, S Larder, B Lackritz, E
Citation: Pj. Weidle et al., Resistance to antiretroviral therapy among patients in Uganda, J ACQ IMM D, 26(5), 2001, pp. 495-500
Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study
Authors: Verbiest, W Brown, S Cohen, C Conant, M Henry, K Hunt, S Sension, M Stein, A Stryker, R Thompson, M Schel, P Van Den Broeck, R Bloor, S Alcorn, T Van Houtte, M Larder, B Hertogs, K
Citation: W. Verbiest et al., Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study, AIDS, 15(5), 2001, pp. 647-650
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samplesfrom heavily treated patients
Authors: Shafer, RW Hertogs, K Zolopa, AR Warford, A Bloor, S Betts, BJ Merigan, TC Harrigan, R Larder, BA
Citation: Rw. Shafer et al., High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samplesfrom heavily treated patients, J CLIN MICR, 39(4), 2001, pp. 1522-1529
Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasma
Authors: Poles, MA Elliott, J Vingerhoets, J Michiels, L Scholliers, A Bloor, S Larder, B Hertogs, K Anton, PA
Citation: Ma. Poles et al., Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasma, J INFEC DIS, 183(1), 2001, pp. 143-148
Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus
Authors: Walsh, KM Woodall, T Lamy, P Wight, DGD Bloor, S Alexander, GJM
Citation: Km. Walsh et al., Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus, GUT, 49(3), 2001, pp. 436-440
HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort
Authors: Miller, V Cozzi-Lepri, A Hertogs, K Gute, P Larder, B Bloor, S Klauke, S Rabenau, H Phillips, A Staszewski, S
Citation: V. Miller et al., HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort, ANTIVIR TH, 5(1), 2000, pp. 49-55
Pigments in the blue pollen and bee pollen of Fuchsia excorticata
Authors: Webby, R Bloor, S
Citation: R. Webby et S. Bloor, Pigments in the blue pollen and bee pollen of Fuchsia excorticata, Z NATURFO C, 55(7-8), 2000, pp. 503-505
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples
Authors: Hertogs, K Bloor, S Kemp, SD Van den Eynde, C Alcorn, TM Pauwels, R Van Houtte, M Staszewski, S Miller, V Larder, BA
Citation: K. Hertogs et al., Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples, AIDS, 14(9), 2000, pp. 1203-1210
Prevalence of genotypic and phenotypic resistance to anti-retroviral drugsin a cohort of therapy-naive HIV-1 infected US military personnel
Authors: Wegner, SA Brodine, SK Mascola, JR Tasker, SA Shaffer, RA Starkey, MJ Barile, A Martin, GJ Aronson, N Emmons, WW Stephan, K Bloor, S Vingerhoets, J Hertogs, K Larder, B
Citation: Sa. Wegner et al., Prevalence of genotypic and phenotypic resistance to anti-retroviral drugsin a cohort of therapy-naive HIV-1 infected US military personnel, AIDS, 14(8), 2000, pp. 1009-1015
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
Authors: Casado, JL Hertogs, K Ruiz, L Dronda, F Van Cauwenberge, A Arno, A Garcia-Arata, I Bloor, S Bonjoch, A Blazquez, J Clotet, B Larder, B
Citation: Jl. Casado et al., Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen, AIDS, 14(2), 2000, pp. F1-F7
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
Authors: Miller, V Sabin, C Hertogs, K Bloor, S Martinez-Picado, J D'Aquila, R Larder, B Lutz, T Gute, P Weidmann, E Rabenau, H Phillips, A Staszewski, S
Citation: V. Miller et al., Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure, AIDS, 14(18), 2000, pp. 2857-2867
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples
Authors: Larder, BA Hertogs, K Bloor, S van den Eynde, C DeCian, W Wang, YY Freimuth, WW Tarpley, G
Citation: Ba. Larder et al., Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples, AIDS, 14(13), 2000, pp. 1943-1948
A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
Authors: Hertogs, K Bloor, S De Vroey, V Van den Eynde, C Dehertogh, P Van Cauwenberge, A Sturmer, M Alcorn, T Wegner, S Van Houtte, M Miller, V Larder, BA
Citation: K. Hertogs et al., A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V, ANTIM AG CH, 44(3), 2000, pp. 568-573
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy
Authors: Harrigan, PR Stone, C Griffin, P Najera, I Bloor, S Kemp, S Tisdale, M Larder, B
Citation: Pr. Harrigan et al., Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy, J INFEC DIS, 181(3), 2000, pp. 912-920
The rabbit study: Ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients
Authors: Churchill, DR Pym, AS Galpin, S Foxall, R Stainsby, C Clarke, JR Kaye, S Bloor, S Larder, BA Wills, B Sun, E Babiker, AG Back, DJ Weber, JN
Citation: Dr. Churchill et al., The rabbit study: Ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients, AIDS RES H, 15(13), 1999, pp. 1181-1189
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
Authors: Harrigan, PR Hertogs, K Verbiest, W Pauwels, R Larder, B Kemp, S Bloor, S Yip, B Hogg, R Alexander, C Montaner, JSG
Citation: Pr. Harrigan et al., Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting, AIDS, 13(14), 1999, pp. 1863-1871
Variation in the ability of the maize Lc regulatory gene to upregulate flavonoid biosynthesis in heterologous systems
Authors: Bradley, JM Deroles, SC Boase, MR Bloor, S Swinny, E Davies, KM
Citation: Jm. Bradley et al., Variation in the ability of the maize Lc regulatory gene to upregulate flavonoid biosynthesis in heterologous systems, PLANT SCI, 140(1), 1999, pp. 31-39
Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms
Authors: Vahey, M Nau, ME Barrick, S Cooley, JD Sawyer, R Sleeker, AA Vickerman, P Bloor, S Larder, B Michael, NL Wegner, SA
Citation: M. Vahey et al., Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms, J CLIN MICR, 37(8), 1999, pp. 2533-2537
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
Authors: Larder, BA Bloor, S Kemp, SD Hertogs, K Desmet, RL Miller, V Sturmer, M Staszewski, S Ren, J Stammers, DK Stuart, DI Pauwels, R
Citation: Ba. Larder et al., A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance, ANTIM AG CH, 43(8), 1999, pp. 1961-1967
Risultati: 1-19 |